文献速递鼻科

过敏性鼻炎多重致敏的隐藏负担:皮下免疫治疗倾向匹配真实世界分析

The Hidden Burden of Polysensitization in Allergic Rhinitis: A Propensity-Matched Real-World Analysis of Subcutaneous Immunotherapy.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-01-21

该回顾性真实世界队列纳入1584例完成3年尘螨皮下免疫治疗的过敏性鼻炎患者,经倾向评分匹配后比较单致敏与多重致敏者的疗效与安全性。匹配后多重致敏者症状改善更少、总体疗效更低(P < .05),局部反应发生率更高(P < .05),全身反应率无差异;多因素回归证实多重致敏是疗效降低和局部反应增加的独立危险因素。

要点

  • 多重致敏者SCIT后1年和3年症状改善及总体疗效均低于单致敏者。
  • 多重致敏者局部反应发生率更高,但全身反应率与单致敏者无差异。
  • 多重致敏是SCIT疗效降低和局部反应增加的独立危险因素。

核心结论

  • 多重致敏与尘螨SCIT疗效降低及局部反应风险增加相关,支持按致敏谱制定个体化SCIT策略并加强监测。

研究设计与样本

  • 大型回顾性真实世界队列研究,纳入2011年1月至2019年1月完成3年尘螨SCIT的过敏性鼻炎患者,按致敏谱分为单致敏与多重致敏组,采用倾向评分匹配平衡基线特征。

主要发现

  • 共纳入1584例患者,其中单致敏994例、多重致敏590例。
  • 匹配前多重致敏者基线症状评分更高、年龄更大、过敏性鼻炎病程更长、剂量调整更频繁、过敏家族史更普遍、哮喘共病更多。
  • 匹配后多重致敏者在SCIT 1年和3年时症状改善显著更少、总体疗效更低(P < .05)。
  • 匹配后多重致敏者局部反应发生率显著更高(P < .05),全身反应率无差异。
  • 多因素回归证实多重致敏是SCIT疗效降低和局部反应增加的独立危险因素(P < .05)。

临床怎么用

  • 对过敏性鼻炎患者启动SCIT前应进行致敏谱评估,识别多重致敏者。
  • 对多重致敏者应预期疗效可能较低并加强局部反应监测,考虑个体化SCIT策略。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy and safety of house dust mite (HDM) subcutaneous immunotherapy (SCIT) between monosensitized and polysensitized allergic rhinitis (AR) patients, and evaluate the independent impact of polysensitization on SCIT outcomes. STUDY DESIGN: Large retrospective real-world cohort study. SETTING: Tertiary referral center. METHODS: AR patients completing a 3-year HDM-SCIT regimen between January 2011 and January 2019 were included. Based on allergen profiles, patients were classified as monosensitized or polysensitized. Propensity score matching balanced baseline characteristics. SCIT efficacy and adverse events were compared before and after matching. Multivariable regression assessed the independent effect of polysensitization on SCIT outcomes. RESULTS: 1584 patients were enrolled (994 monosensitized and 590 polysensitized). Before matching, polysensitized patients exhibited higher baseline symptom scores, older age, longer AR duration, more frequent dose modifications, greater prevalence of family history of allergy, and increased asthma comorbidity. After matching, polysensitized patients showed significantly less symptom improvement and lower overall efficacy at both SCIT 1 and 3 years (P < .05). The incidence of local reactions (LRs) was also significantly higher (P < .05), while systemic reaction rates did not differ. Multivariable regression confirmed polysensitization as an independent risk factor for reduced SCIT efficacy and increased LRs (P < .05). CONCLUSION: Polysensitization was linked to reduced SCIT efficacy and a higher risk of LRs. These results underscore the value of allergen profiling and support personalized SCIT strategies and closer monitoring for polysensitized patients.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Yuan X, Liu L, Xie S, et al. The Hidden Burden of Polysensitization in Allergic Rhinitis: A Propensity-Matched Real-World Analysis of Subcutaneous Immunotherapy. Otolaryngol Head Neck Surg. 2026. PMID: 41566908. doi:10.1002/ohn.70130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。